Charles C. Morris, Inc. – Trademark Portfolio

Entity Type: 03

Charles C. Morris, Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include [PRESCRIPTION SYMBOL] CLEAR. The owner is based in Pottsville, PA.

RD # 1

Pottsville, PA 17901

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Charles C. Morris, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Charles C. Morris, Inc. have?

Charles C. Morris, Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 cancelled.

What trademark classes does Charles C. Morris, Inc. file in?

Charles C. Morris, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Charles C. Morris, Inc.'s most well-known trademarks?

Charles C. Morris, Inc.'s registered trademark portfolio includes well-known marks such as [PRESCRIPTION SYMBOL] CLEAR. These are among 1 currently registered trademark in the portfolio.

What is Charles C. Morris, Inc.'s trademark registration success rate?

Charles C. Morris, Inc. has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.